Grifols (GRFS) Research & Development (2009 - 2018)
Grifols (GRFS) posted Research & Development of $69.6 million for Q2 2018, up 1.37% quarter-over-quarter from $68.6 million in Q2 2017, and up 1.37% year-on-year from $68.6 million in Q2 2017.
Grifols (GRFS) Research & Development (2009 - 2018) Analysis & Trends
Grifols (GRFS) has reported Research & Development for 8 consecutive years, with $69.6 million the latest figure, recorded in Q2 2018.
- Research & Development for Q2 2018 came in at $69.6 million, up 1.37% year-over-year; the trailing twelve-month figure through Jun 2018 was $571.5 million (up 2.4% YoY), and the FY2025 annual result was $495.9 million, up 20.85% from the prior year.
- Research & Development was $69.6 million for Q2 2018 at Grifols, up from $68.6 million in the prior quarter.
- Over five years, Research & Development peaked at $375.0 million in Q4 2016 and troughed at -$57.5 million in Q1 2015.
- Average Research & Development over 4 years is $84.6 million, with a median of $60.3 million recorded in 2015.
- The widest YoY moves for Research & Development: up 417.84% in 2016, down 4.2% in 2016.
- Over 4 years, Research & Development stood at $72.4 million in 2015, then jumped by 417.84% to $375.0 million in 2016, then sank by 81.7% to $68.6 million in 2017, then grew by 1.37% to $69.6 million in 2018.
- Per Business Quant data, the three most recent Research & Development figures were $69.6 million in Q2 2018, $68.6 million in Q2 2017, and $375.0 million in Q4 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.51 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 3.53 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 2.47 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -3.49 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 69.56 Mn |
| Jun 30, 2017 | 68.62 Mn |
| Dec 31, 2016 | 374.96 Mn |
| Sep 30, 2016 | 58.39 Mn |
| Jun 30, 2016 | 56.14 Mn |
| Dec 31, 2015 | 72.41 Mn |
| Sep 30, 2015 | 60.28 Mn |
| Jun 30, 2015 | 58.59 Mn |
| Mar 31, 2015 | -57.53 Mn |
| Dec 31, 2014 | 66.51 Mn |
| Sep 30, 2014 | 56.20 Mn |
| Jun 30, 2014 | 64,888.16 |
| Mar 31, 2014 | 51.93 Mn |
| Dec 31, 2013 | 44.93 Mn |
| Sep 30, 2013 | 42.12 Mn |
| Jun 30, 2013 | 38.08 Mn |
| Mar 31, 2013 | 38.70 Mn |
| Dec 31, 2012 | 44.19 Mn |
| Sep 30, 2012 | 39.60 Mn |
| Jun 30, 2012 | 39.02 Mn |